Keros Therapeutics Inc at TD Cowen Healthcare Conference Transcript
Good morning everyone and welcome to TD Cowen's 46th Annual Healthcare Conference. For our next session we have Keros Therapeutics, and I am pleased to welcome Jasbir S. Seehra from the company, the CEO of the company. This is a hybrid presentation followed by a Q&A session, so we will get started with the presentation now whenever you are ready. Jasbir, please go ahead.
Thank you, Nate. I want to thank TD Cowen for giving us the opportunity to talk today. I will be making some forward-looking statements, and the risks associated are in our quarterly filing and the 10-Q filed with the SEC in November 2025, so please take a look at that. Keros is a clinical-stage biopharmaceutical company focused on the TGF-beta pathway, which is active throughout embryogenesis and adulthood and can lead to pathology when imbalanced.
We believe we have product candidates that can fully unlock the therapeutic benefit of this pathway, and with that I will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
